K
Kelly Bleasby
Researcher at Merck & Co.
Publications - 21
Citations - 1099
Kelly Bleasby is an academic researcher from Merck & Co.. The author has contributed to research in topics: Organic anion transporter 1 & Organic anion-transporting polypeptide. The author has an hindex of 13, co-authored 20 publications receiving 971 citations.
Papers
More filters
Journal ArticleDOI
Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition.
Kelly Bleasby,John C. Castle,Christopher J. Roberts,C.-H. Christina Cheng,Wendy J. Bailey,Joseph F. Sina,Amit Kulkarni,Michael J. Hafey,Raymond Evers,Jason M. Johnson,Roger G. Ulrich,J. G. Slatter +11 more
TL;DR: A comprehensive data set of xenobiotic transporter gene expression profiles in humans and the pre-clinical species mouse, rat, beagle dog and cynomolgus monkey is generated.
Journal ArticleDOI
Species differences in drug transporters and implications for translating preclinical findings to humans
TL;DR: This article provides an overview of species differences for the major transporters involved in drug disposition and suggests high quality in vitro and in vivo data will aid in the establishment of physiologically based pharmacokinetic (PBPK) models, which will improve the capability to predict PK characteristics of drug candidates in humans.
Journal ArticleDOI
Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-glycoprotein
Xiaoyan Chu,Kelly Bleasby,Jocelyn Yabut,Xiaoxin Cai,Grace Chan,Michael J. Hafey,Shiyao Xu,Arthur J. Bergman,Matthew P. Braun,Dennis C. Dean,Raymond Evers +10 more
TL;DR: The data indicate that sitagliptin is unlikely to be a perpetrator of drug-drug interactions with Pgp, hOAT1, or hOat3 substrates at clinically relevant concentrations, and the effects may not be clinically meaningful, due to the high safety margin of sitgliptin.
Journal ArticleDOI
Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.
Renata Oballa,Liette Belair,W. Cameron Black,Kelly Bleasby,Chi-Chung Chan,Carole Desroches,Xiaobing Du,R. Gordon,Jocelyne Guay,Sébastien Guiral,Michael J. Hafey,Emelie Hamelin,Zheng Huang,Brian P. Kennedy,Nicolas Lachance,Chun Sing Li,Joseph A. Mancini,Denis Normandin,Alessandro Pocai,David A. Powell,Yeeman K. Ramtohul,Kathryn Skorey,Dan Sørensen,Wayne Sturkenboom,Angela Styhler,Deena Waddleton,Hao Wang,Simon Wong,Lijing Xu,Lei Zhang +29 more
TL;DR: The discovery of MK-8245 is found, a potent, liver-targeted SCD inhibitor with preclinical antidiabetic and antidyslipidemic efficacy with a significantly improved therapeutic window.
Journal ArticleDOI
The Complexities of Interpreting Reversible Elevated Serum Creatinine Levels in Drug Development: Does a Correlation with Inhibition of Renal Transporters Exist?
TL;DR: The challenges associated with using creatinine as a marker for kidney damage are discussed and whether reversible changes in SCr can be predicted prospectively based on in vitro transporter inhibition data is evaluated.